Coinbase To Enable Perpetual Futures For Eligible Non-US Retail Customers

Coinbase International Exchange, initially established for non-U.S. institutional trading, has secured regulatory clearance from the Bermuda Monetary Authority (BMA) to offer perpetual futures trading to non-U.S. retail customers.

Coinbase International Exchange, initially established for non-U.S. institutional trading, has secured regulatory clearance from the Bermuda Monetary Authority (BMA) to offer perpetual futures trading to non-U.S. retail customers.

This move aligns with the discussions at Benzinga’s Future of Digital Assets conference on Nov. 14, emphasizing the evolving landscape of digital asset trading.

What Happened: The decision to expand access to the global derivatives market came as part of Coinbase’s “Go Broad, Go Deep” strategy.

In a blog post, Coinbase stated that while it advocates for the U.S. to lead in updating the financial system, this recent development signifies its intent to modernize the global financial system, aiming to provide more economic freedom to users worldwide.

Also Read: EXCLUSIVE: Bittrex CEO Discusses Blockchain, DeFi And Trouble With UK Regulators

Coinbase’s perpetual futures contracts, available on the International Exchange, have already recorded more than $5.5 billion in notional trading volume from institutions by the end of the second quarter, it stated.

The company attributed this success to its adherence to the BMA’s regulatory framework, emphasizing risk management, compliance and user protection.

Distinguishing itself from competitors, Coinbase stated it assured customers of the safety of their assets, backed by audited financial statements that confirmed a 1:1 holding of customer assets.

Additionally, the International Exchange boasts a well-funded Insurance Fund and Liquidity Support Program, primarily in USD Coin (CRYPTO: USDC).

Coinbase further stated it refrained from market-making, relying instead on vetted, independent liquidity providers.

Read Next: Gemini Withdrew $282M From Genesis Global Months Before Bankruptcy Filing: Report

Meet and engage with transformative Digital Asset and Crypto business leaders and investors at Benzinga’s exclusive event: Future of Digital Assets. Tickets are flying: Get yours

Photo: Shutterstock

Total
0
Shares
Related Posts
Read More

Cogent Biosciences Announced Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosisl; Announced 89% ORR in TKI-therapy Naïve Patients; 73% ORR in All Evaluable Patients with 27-wee…

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated clinical data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic m

COGT